Dianthus Therapeutics, Inc.
DNTH
$24.33
$0.923.93%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -31.63M | -29.51M | -28.44M | -25.17M | -17.61M |
| Total Depreciation and Amortization | -76.00K | 133.00K | 78.00K | 289.00K | -62.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 4.76M | 3.41M | 1.34M | 1.02M | 2.85M |
| Change in Net Operating Assets | 3.05M | -1.66M | -422.00K | 2.60M | 289.00K |
| Cash from Operations | -23.89M | -27.63M | -27.44M | -21.27M | -14.53M |
| Capital Expenditure | -46.00K | -24.00K | -31.00K | -25.00K | -17.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 26.49M | 14.82M | -23.08M | -259.34M | 1.19M |
| Cash from Investing | 26.45M | 14.79M | -23.11M | -259.36M | 1.17M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 568.00K | 161.00K | 39.68M | 296.00K | 47.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 0.00 | 0.00 | -2.24M |
| Cash from Financing | 568.00K | 161.00K | 39.68M | 296.00K | -2.20M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 3.12M | -12.68M | -10.88M | -280.34M | -15.56M |